Femasys (NASDAQ:FEMY – Get Free Report) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.
Other research analysts also recently issued reports about the company. Lake Street Capital reduced their target price on Femasys to $10.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. Maxim Group decreased their target price on Femasys to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, Weiss Ratings cut shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.00.
Read Our Latest Report on FEMY
Femasys Stock Performance
FEMY stock opened at $1.65 on Friday. The company’s 50-day simple moving average is $2.48 and its 200-day simple moving average is $4.68. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89. Femasys has a 52-week low of $1.46 and a 52-week high of $22.20. The firm has a market cap of $13.82 million, a P/E ratio of -0.47 and a beta of -2.16.
Femasys (NASDAQ:FEMY – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%. The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.73 million.
Insider Activity
In other news, CFO Dov Elefant acquired 15,625 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the acquisition, the chief financial officer owned 15,625 shares in the company, valued at approximately $50,000. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kathy Lee-Sepsick acquired 15,625 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the chief executive officer owned 15,625 shares in the company, valued at $50,000. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 38,750 shares of company stock valued at $124,000. Insiders own 7.75% of the company’s stock.
Femasys Company Profile
Femasys Inc is a biomedical company focused on developing and commercializing therapies and technologies for women’s health. The company’s products are designed to address reproductive health needs, including contraception and infertility, through minimally invasive procedures intended to be performed in a physician’s office.
Femasys’ product portfolio includes FemaSeed, an FDA-cleared intratubal insemination system designed to deliver sperm directly into the fallopian tube during an infertility treatment procedure.
Further Reading
- Five stocks we like better than Femasys
- These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
- Meta Claims Frontier-Class AI Status With New Muse Wonder Models
- Berkshire Just Backed This Little-Known Stock—Should You Chase It?
- Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
